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Abstract
Granulomatosis with polyangiitis is an ANCA-associated systemic vasculitis with a low incidence in the pediatric
population. Lung involvement is a common manifestation in children affected by granulomatosis with polyangiitis,
both at disease’s onset and during flares. Its severity is variable, ranging from asymptomatic pulmonary lesions to
dramatic life-threatening clinical presentations such as diffuse alveolar haemorrhage. Several radiologic findings have
been described, but the most frequent abnormalities detected are nodular lesions and fixed infiltrates. Interstitial
involvement, pleural disease and pulmonary embolism are less common. Histology may show necrotizing or
granulomatous vasculitis of small arteries and veins of the lung, but since typical features may be patchy, the site for
lung biopsy should be carefully chosen with the help of imaging techniques such as computed tomography.
Bronchoalveolar lavage is helpful to confirm the diagnosis of alveolar haemorrhage. Pulmonary function tests are
frequently altered, showing a reduction in the diffusion capacity for carbon monoxide, which can be associated with
obstructive abnormalities related to airway stenosis. Nodular lung lesions tend to regress with immunosuppressive
therapy, but lung disease may also require second line treatments such as plasmapheresis. In cases of massive diffuse
alveolar haemorrhage, ventilator support is crucial in the management of the patient.
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Background
Granulomatosis with polyangiitis (GPA), formerly known
as Wegener’s granulomatosis [1], is an idiopathic vasculitis
of medium and small arteries, characterized by necrotizing
granulomatous inflammation of the respiratory tract with
necrotizing, pauci-immune glomerulonephritis; vasculitis
frequently involves also other organs. GPA is a member of
a family of vasculitides associated with positive anti-
neutrophil cytoplasmic antibodies (ANCA). In GPA, the
pattern of autoantibody staining of ethanol-fixed neutro-
phils is typically cytoplasmic (c-ANCA), rather than peri-
nuclear (p-ANCA), due to the presence of antibodies
against proteinase 3, which is a constituent of the azuro-
philic granules of the neutrophil [2, 3].
The family of ANCA-associated vasculitides (AAV) also
includes eosinophilic granulomatosis with polyangiitis
(EGPA, previously known as Churg-Strauss syndrome)
and microscopic polyangiitis (MPA). The clinical spectrum
of vasculitides is broad; the lack of pathognomonic
features and the presence of overlapping clinical manifes-
tations makes diagnosis challenging, especially in discrim-
inating one form from one another. In 1990 the American
College of Rheumatology (ACR) published the classifica-
tion criteria for seven vasculitides, including GPA and
EGPA [4–7]. However, because of the poor performance
of ACR criteria in classifying children with vasculitis, the
EULAR/PRINTO/PRES criteria were developed using
pediatric data. The EULAR/PRINTO/PRES criteria for
GPA (Table 1) showed improved sensitivity compared to
the adult-based ACR criteria (93% vs 83%) [8–10]. How-
ever, both classification criteria did not include MPA,
which had its specific definition thanks to the Chapel Hill
Consensuses Conference (CHCC) [11]. It is therefore pos-
sible that cases classified as GPA according to ACR criteria
may be described as MPA using the CHCC definition. In
2007 the European Medicines Agency (EMA) endorsed a
classification algorithm to classify patients with a mutually
exclusive diagnosis (EGPA, GPA, MPA, or polyarteritis
nodosa) [12]. The EMA classification algorithm showed to
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be a promising tool to uniquely diagnose children with
either GPA or MPA [13].
GPA onset usually occurs between 45 and 60 years of
age, with a peak in the sixth decade [2, 14, 15], but in a
small proportion of cases (3.3–7%) it may affect also
children and adolescents. Incidence of juvenile onset
GPA is not well known but estimates range from 0.02 to
0.64 per 100,000 persons per year [16, 17]. Pediatric
GPA is usually diagnosed in adolescence [18–33], with a
median age at onset of 11.6 years and a median age at
diagnosis of 14 years, and presents a female predomin-
ance with a male to female ratio of 1:2.1 [18].
The most common clinical manifestations of childhood
GPA at onset are related to upper airway involvement
(82%), nephropathy (65%) and lower respiratory tract dis-
ease (61%). This characteristic triad is frequently associ-
ated with systemic symptoms (73%) [18]. Although the
main aim of this review is to present lung involvement in
GPA, upper airway disease is briefly summarized below in
the next paragraph, as it affects respiratory findings in
patients with GPA.
According to the EULAR/PRINTO/PRES criteria, upper
airway involvement can be assessed in presence of chronic
or bloody nasal discharge, recurrent epistaxis/crusts/granu-
lomata, septal perforation or sinus inflammation [9]. Sino-
nasal disease is a common presenting feature of GPA in
children, which should be distinguished from infectious or
allergic rhinitis or rhinosinusitis [18, 24, 32]. Longstanding
disease can damage nasal cartilage, leading to septal perfor-
ation and saddle-nose deformity. Other manifestations of
ear, nose and throat involvement include otitis, mastoiditis,
oral ulcers or granulomata, mucocele, hearing loss and
subglottic stenosis [19, 21, 22, 24, 33]. Young patients
under 20 years of age are more prone to develop tracheal
involvement [34]; subglottic stenosis was reported to com-
plicate childhood GPA five times as often as in adults [17].
Therefore, laryngo-tracheo-bronchial stenosis was included
in the pediatric EULAR/PRINTO/PRES criteria [9]. In a
cohort of 28 pediatric patient affected by GPA, airway sten-
osis was detected in 36% of patients at diagnosis and in
50% during follow-up, with involvement of the tracheo-
bronchial tree in a third of cases [35]. The common symp-
toms caused by tracheobronchial involvement include
hoarseness, cough, dyspnea, stridor, and wheezing [36–38].
Lung involvement in childhood-onset GPA
Prevalence and clinical features
Lung involvement is a frequent feature of GPA. Main
features of lung involvement in children with GPA are
displayed in Table 2. X-ray evidence of fixed pulmonary
Table 1 EULAR/PRINTO/PRES criteria for childhood granulomatosis
with polyangiitis [6]
1. Histopathology Granulomatous inflammation within the
wall of an artery or in the perivascular
or extravascular area
2. Upper airway
involvement
Chronic purulent or bloody nasal discharge
or recurrent epistaxis/crusts/granulomata
Nasal septum perforation or saddle nose
deformity
Chronic or recurrent sinus inflammation
3. Laryngo-tracheo-bronchial
involvement
Subglottic, tracheal or bronchial stenosis
4. Pulmonary involvement Chest x-ray or CT showing the presence
of nodules, cavities or fixed infiltrates
5. ANCA ANCA positivity by immunofluorescence
or by ELISA (MPO/p or PR3/c ANCA)
6. Renal involvement Proteinuria >0.3 g/24 h or >30 mmol/mg
of urine albumin/creatinine ratio on a
spot morning sample
Haematuria or red blood cell casts: >5
red blood cells/high power field or red
blood cells casts in the urinary sediment
or ≥2+ on dipstick
Necrotising pauci-immune
glomerulonephritis
The presence of at least three of the six criteria has a sensitivity of 93.3% and
a specificity of 99.2% in confirming the diagnosis
Table 2 Frequency and main features of lung involvement in patients affected with GPA in pediatric series
First author and
year of publication
Number
of patients
Median age at
diagnosis (range)
Female Lung
involvement (%)
Hemopstysis/Alveolar
haemorrage
Dyspnea Chronic cough Pleural effusion/
thickening
Lung nodules
or cavity
Lung
infiltrate
Tahghighi 2013 [23] 11 11 (6–15) 5 7 (63,6%) 2 2 N.R. 1 N.R. N.R.
Iudici 2015 [25] 25 14 (2–17) 18 17 (68%) 3 3 N.R. N.R. 7 6
Sacri 2015 [26] 28 12,8 (10,1–14,6) 21 19 (67,8%) 12 N.R. N.R. 1 7 16
Bohm 2014 [30] 56 N.R. 38 44 (78,5%) 14/55 N.R. N.R. 7 17 26/55
Kosalka 2014 [31] 9 N.R. 6 8 (88,9%) 4 N.R. N.R. 2 4 2
Cabral 2016 [32] 183 14 (2–18) 113 136 (74,3%) 76 15 99 25 97 64
Belostotsky 2002 [33] 17 N.R. 13 14 (82,3%) 3 4 9 N.R. 2 2
Akikusa 2007 [22] 25 14,5 (8,7–17,1) 20 21 (84%) 12 N.R. N.R. 2 13 6
Arulkumaran 2011 [27] 7 N.R. 5 5 (71,4%) 2 N.R. N.R. N.R. N.R. N.R.
Wong 1998 [28] 12 N.R. 8 7 (58,3%) 3 N.R. N.R. N.R. N.R. N.R.
N.R. not reported
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infiltrates, nodules, or cavitations for more than 1 month
essentially precludes a diagnosis of MPA according to the
EMA algorithm to classify vasculitis [12]. MPA is a nec-
rotizing vasculitis with few or no immune deposits, pre-
dominantly affecting small vessels (capillaries, venules,
or arterioles) and more rarely small- and medium-sized
arteries [11]. The limited available literature suggests
that genetic, pathophysiological and prognostic differ-
ences exist between MPA and GPA, but distinguishing
between these diseases is challenging because of over-
lapping clinical features. The absence of granulomata
and sparing of the upper respiratory tract are features
of MPA, in which necrotizing glomerulonephritis and
pulmonary capillaritis are common. These features help
to distinguish MPA from GPA [11].
Lung disease is frequently the presenting clinical mani-
festation of GPA, however it can sometimes develop
later during the disease course. Pulmonary involvement
is frequent during disease’s flares, also in patients who
did not present lung disease at GPA onset [22].
In the ARChiVe (A Registry for Children with Vasculitis)
cohort including 65 children affected by GPA, shortness
of breath was reported in 58.5% of cases and chronic
cough in 52.3% [20]. In a subsequent study on the ARCh-
iVe cohort, including 183 patients with childhood-onset
GPA, pulmonary involvement was detected in 74% of pa-
tients. Overall, 54% of patients presented chronic cough,
while only 8% showed wheezing or expiratory dyspnea.
Massive haemoptysis or alveolar haemorrhage was re-
ported in 42% of patients. Chest imaging was abnormal in
89% of patients, showing nodules in 54% of cases, fixed
pulmonary infiltrates in 36% and cavitations in 21%; other
findings such as fibrosis, septal thickening and pneumo-
thorax were detected in less than 10% of cases. Pleurisy af-
fected 14% of patients: 12% of patients had respiratory
failure and 22% required supplemental oxygen. In 31 pa-
tients lung biopsy was performed: in 77% of cases biopsy
findings confirmed the presence of vasculitis or were con-
sistent with features of vasculitis [32].
In the meta-analysis published by Iudici et al., lower re-
spiratory tract involvement has a prevalence of 61% (95%
confidence interval [CI] 48–74%), with hemoptysis/alveo-
lar haemorrage occurring in 16% of patients and lung
nodules identified in 10% of patients [18].
It should be noted that Rottem et al. reported that 41%
of radiographic abnormalities found in patients with child-
hood GPA were observed in absence of symptoms. [21]
Manifestations of lung involvement during flares are
variable, but in a pediatric series of 25 patients, alveolar
haemorrhage was reported to be the least common condi-
tion observed [22]. Considering mortality in childhood
GPA, together with infections, respiratory complications
(including pulmonary haemorrhage and chronic lung dis-
ease) were the most common causes of death [25, 32].
Nodules
Nodular lesions are the most common pulmonary
radiologic finding in GPA, in both adults and children
[22, 32, 39]. Their presence is not necessarily associ-
ated with clinical signs and symptoms. [21] They con-
sist of granulomatous inflammation and necrosis. In
children both multiple and single nodular lesions have
been described; on chest radiography, their size may vary
from 1 to 4 cm [29, 39–41]. In adult patients, nodules are
usually multiple but in a number not greater than ten,
with a size ranging from 1 to 10 cm [39]. Computed tom-
ography (CT) shows also smaller nodules and can detect
intranodular cavitation, that cannot be seen on chest x
rays. Without treatment, nodules increase in number and
size and tend to cavitate.
Pulmonary nodules usually regress with therapy in weeks
or months, but local scarring is possible. Persistent nodules
may indicate active disease, but could also be due to cica-
tricial residues in patients with inactive disease [39, 42].
The absence of regression or the extension of the lesion in
a patient who is receiving immunosuppressive treatment
may also be caused by a bacterial superinfection [43].
Diffuse alveolar haemorrhage
Diffuse alveolar haemorrhage is a life-threatening condi-
tion which presents with haemoptysis, anemia, and diffuse
alveolar infiltrates leading to respiratory failure. The clin-
ical triad is often incomplete, in particular hemoptysis
may be absent in about a third of cases [44]. Hypocomple-
mentemia at the time of diagnosis was recognized as a risk
factor for alveolar haemorrage [45].
Chest radiography shows a bilateral alveolar filling
pattern, involving perihilar and basal lung fields. Bron-
chial fibroscopy shows a peripheral diffuse bleeding,
and is required to exclude a localized cause of hemor-
rage. Bronchoalveolar lavage (BAL) allows detection of
blood red cells if the haemorrhage is acute or sidero-
phages if it is chronic; furthermore, it is useful in ruling
out infections, that may be suspected also due to the
presence of constitutional symptoms such as fever [39].
The underlying histologic findings of diffuse alveolar
haemorrage are neutrophilic infiltration and fibrinoid
necrosis of the alveolar and capillary walls [46].
A study in the adult population showed that in pa-
tients with alveolar haemorrage due to AAV, the degree
of hypoxemia upon presentation was the most import-
ant predictor of respiratory failure; a higher disease ac-
tivity score, a higher percentage of neutrophils in the
BAL fluid and higher C reactive protein levels were also
associated with respiratory failure [47].
Other manifestations
Pulmonary fibrosis is uncommon in patients with anti-
neutrophil cytoplasmic antibodies-associated vasculitis
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and mainly occurs in microscopic polyangiitis in associ-
ation with anti-MPO antibodies; nonetheless, it was de-
scribed in adult patients affected with GPA [48–51] and
also in pediatric patients [32]. Interstitial involvement in
a treated patient should induce the suspicion of a iatro-
genic pneumopathy [39, 52].
Pleural involvement is present in a minority of pa-
tients, and may consist of pleural thickening, pneumo-
thorax or pyopneumothorax, which can be caused by
the rupture of a peripheral cavitated lesion into the
pleural cavity.
It should be remembered that GPA is associated with
an increased risk of venous thromboembolic events in
adults and children: although in a small proportion of
cases, also pulmonary embolic disease has been de-
scribed in patients with childhood onset GPA, both at
disease presentation and during follow-up [22, 53, 54].
Necrotizing granulomas not only alter the normal al-
veolar architecture progressively impairing the respira-
tory function, but may also cause bronchial stenosis.
Multilevel airway stenosis was described in about one
third of adult patients, in particular 17% had mid/distal
tracheal stenosis and 11% had bronchial stenosis [55]. In
children affected by GPA, tracheobronchial stenosis was
detected in 17% of cases [35].
Histological findings
The simplest approach to collect tissue for histological
analysis is transbronchial biopsy, but blind transbron-
chial biopsy of lung tissue is rarely informative because
of the focal distribution of the inflammatory lesions in
GPA. Open-lung biopsy has a higher accuracy, but also
more significant morbidity [56–58]. Computed tomog-
raphy may help in choosing the best site for tissue sam-
pling, in order to increase the yield of transbronchial
biopsy; lesions with little necrotic component should be
preferred. In adults, image-guided automated core nee-
dle biopsy was even used to obtain histological proof of
disease activity and guide therapy [59].
Necrotizing or granulomatous vasculitis may be
found in small arteries and veins of the lung. The
lumen of the vessels may be occluded by inflammatory
infiltrate or by a thrombus [60]. Granulomas show cen-
tral necrosis surrounded by histiocytes, lymphocytes
and giant cells; also eosinophils may be present but in
small proportion. In some cases nonspecific inflamma-
tion may be found [17].
Histology in pulmonary haemorrhage generally shows
pulmonary capillaritis, which consists of interstitial neu-
trophilic predominant infiltration, fibrinoid necrosis of
the alveolar and capillary walls and leukocytoclasis, with
subsequent loss of the integrity of the alveolar capillary
membrane [46].
Radiologic findings
The typical lower respiratory tract involvement of GPA
is demonstrated by radiologic findings of lung nodules,
cavities or fixed infiltrates. In adults the most common
radiological presentation is represented by multiple
nodules randomly distributed throughout the lung, of
variable size as mentioned above. They range from well
to poorly defined and may be distributed along broncho-
vascular bundles. In approximately a half of cases, some
of the nodules demonstrate cavitation, which is best seen
by CT [61, 62].
Presence of nodules was the most frequent observation
also in pediatric patients (Fig. 1) [22, 32]. However, in a
small cohort of children, diffuse interstitial and alveolar
opacities attributable to pulmonary hemorrhage were
more common than nodular lesions [41]. Both nodules
and regions of consolidation can be surrounded by haem-
orrhage, which in some cases dominates the radiographic
appearance. Unfortunately, the radiographic appearance
of GPA is very variable and not specific, making a diagno-
sis by imaging alone often difficult [39].
Conventional chest X rays can easily detect nodules
and masses, fixed infiltrates, cavitations, pleural effusions
and pneumothoraces, while small nodules, linear opaci-
ties, focal infiltrates and fluffy perivascular densities are
best identified using high-resolution computed tomog-
raphy (HRCT) [17] (Fig. 2). Bilateral perihilar and basal
infiltrates of alveolar haemorrhage may resemble pul-
monary oedema, but differential diagnosis can be based
Fig. 1 Chest x ray in a 16-year old girl affected by granulomatosis with
polyangiitis (GPA). The image shows multiple nodular lesions together
with diffuse opacities in the lower and middle regions of the lung
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on the absence of cardiomegaly and signs of venous
hypertension. Following acute diffuse alveolar haemor-
rage, a radiographic pattern of septal thickening, known
as crazy-paving, can appear [62].
The most common HRCT abnormalities are lung nod-
ules, usually multiple and bilateral which tend to in-
crease with disease progression. They can range from
few millimeters to >10 cm in diameter and become cavi-
tated. Cavities are usually thick walled and characterized
by an irregular inner margin and absent calcification.
The nodular lesions are often related to the vessels, and
they tend to involve mainly the subpleural regions but
have no predilection for the upper or lower lung zones.
Haemorrhage may result in a HRCT finding consisting
of an edge of ground glass opacity surrounding the lung
lesion, known as halo sign [62, 63]. HRCT could be used
also to identify active disease: ground-glass opacities,
cavitations and masses measuring more than 3 cm tend
to correspond to active disease; while non-cavitated
small nodules and linear opacities can also represent
cicatricial lesions [64].
18-F-fluorodeoxyglucose positron emission tomog-
raphy/computed tomography scans have been used to
evaluate global disease distribution and to identify active
lesions suitable for biopsy [65, 66].
Pulmonary function tests
When tested for pulmonary function, patients affected
by GPA most commonly show airflow obstruction, often
in association with a reduced diffusion capacity of the
lung for carbon monoxide. Reduction of lung volumes
has also been described [67, 68]. In a pediatric series, of
the 35 patients who performed pulmonary function
tests, 27 had abnormal results, with obstructive and re-
strictive abnormalities detected in the same proportion
of cases [20]. Sixty-seven patients of the ARChiVe co-
hort performed pulmonary function tests, which were
abnormal in 61% of cases [32]. Since pulmonary involve-
ment in GPA may be initially asymptomatic, it should be
investigated not only radiographically, but also with
pulmonary function testing. The first sign of pulmonary
haemorrhage may be an alteration in the diffusion cap-
acity of the lung for carbon monoxide [21, 57, 69]. In
patients with subglottic stenosis, the flow-volume curve
shows a flattening in both inspiratory and expiratory phase,
consistent with an extrathoracic airway obstruction [70].
Differential diagnosis
In the presence of lung disease, concomitant upper
airway and kidney involvement can guide the clinician
towards GPA diagnosis. Other conditions associated
with pulmonary-renal syndrome, such as Goodpasture’s
syndrome, polyarteritis nodosa, systemic lupus eythema-
tosus or mixed connective tissue disease, should be
excluded. Laboratory evidence of positive ANCA, in par-
ticular c-ANCA or PR3-ANCA, and a compatible kidney
biopsy, are supportive findings of GPA diagnosis. Lung
involvement of ulcerative colitis associated with ANCA
positivity may also mimic GPA [71].
Considering nodular lung lesions, neoplastic disease
and sarcoidosis should also be suspected. In children,
also chronic granulomatous disease has to be considered
[72]. Other causes of alveolar haemorrhage described in
the pediatric population are idiopathic pulmonary hae-
mosiderosis and childhood onset systemic lupus erythe-
matosus [73–75].
Another important differential diagnosis is with infec-
tious processes, in particular mycobacterial, micotic or
helmintic infections [76]. Diffuse alveolar haemorrhage
has been described as a consequence of pulmonary
histoplasmosis [77]. It should also be remembered that
lung disease in GPA patients may also be due to con-
comitant infections, in particular Pneumocystis jirovecii
infection in the immunocompromised patient [78, 79].
Treatment
Treatment requires a remission induction phase, followed
by maintenance therapy. Standard treatment of GPA has
primarily consisted of glucocorticoids and cyclophospha-
mide. Several other immunosuppressive agents have been
used, in monotherapy or in combination with glucocor-
ticoids, including methotrexate, azathioprine, mycophe-
nolate, cyclosporine, colchicines, etanercept, infliximab,
Fig. 2 High-resolution chest computed tomography in a 16-year old girl
affected by granulomatosis with polyangiitis (GPA). The image shows
multiple nodules and regions of consolidation of variable size, irregularly
marginated with peribronchovascular distribution. Cavitations are
demonstrated in several nodules, the largest in the right lung (6.5×4.5 cm).
Diffuse alveolar opacities are consequence of haemorrhages
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adalimumab, rituximab. Remission induction is mainly
based on the use of glucocorticoids and cyclophospha-
mide; cyclophosphamide can be administered either orally
or with intravenous pulses and should be withdrawn when
remission is achieved. Remission maintenance therapy,
which should last at least 18–24 months, is usually
based on the introduction of azathioprine or metho-
trexate, with concomitant tapering of glucocorticoids
[18, 19, 21, 80–84].
Other therapeutic strategies have been used in severe
and refractory cases. Intravenous immunoglobulin ad-
ministration has been used as adjunctive therapy in AAV
patients with refractory or relapsing disease, even if
11,9% of patients presented serious adverse events [85].
In severe cases of alveolar haemorrage, together with ag-
gressive immunosuppressive therapy, plasmapheresis has
been used [86]. The use of plasma exchange in patients
with creatinine levels > 5,8 mg/dl was proved to be more
effective than intravenous methylprednisolone in pre-
venting end-stage renal disease at 12 months, but no dif-
ference was observed in survival rates and incidence of
adverse events [87]. Even if plasma exchange is usually
reserved for refractory disease and life-threatening con-
ditions, it has been proposed also for induction of remis-
sion in less severe cases [88]. The PEXIVAS study will
better define the benefits of plasma exchange in AAV.
[89] Kidney involvement may require dialysis and kidney
transplant [90].
So far, no clinical trial has been conducted in the
pediatric population and no pediatric specific recom-
mendations are available. Pediatric guidelines for GPA
will be hopefully developed by the SHARE project,
whose aim is to provide recommendations for the care
of children and young adults with rheumatic diseases,
including vasculitis [91]. At the moment, therapeutic
management is guided by data extrapolated from adult
studies. Guidelines for the treatment of AAV in adult pa-
tients have recently been published [92, 93].
Of note, both British and EULAR recommendations
include rituximab, an anti-CD20 monoclonal antibody,
which has proved to be a promising new therapeutic
option for AAV both in remission induction and in
remission maintenance [92–96]. The RAVE trial, which
included AAV patients older than 15 years, showed that
rituximab was not inferior to cyclophosphamide in
achieving remission induction and was more effective
for relapsing disease; better response to rituximab was
observed in anti-PR3 positive patients [94]. Rituximab
should be considered as a therapeutic option for remis-
sion induction also in children, since steroid sparing in
pediatric age is mandatory and cyclophospahmide avoid-
ance is especially desirable in young people at risk of
infertility. In a pediatric series, 10 patients with primary
systemic vasculitis, including 4 children with GPA, were
treated with rituximab with a decrease in disease activity
and in corticosteroid dose. Of 10 patients receiving
rituximab, 3 presented adverse events: one patient with
unclassified vasculitis had mild headache with second
rituximab infusion; one patient with GPA developed par-
onychia 2 months after receiving rituximab treatment;
one patient with GPA treated with both infliximab and
rituximab presented, respectively 9 and 7 months after
drug discontinuation, a Pseudomonas urinary tract infec-
tion and concurrent pneumonia, while he was also being
administered concurrent immunosuppressive therapy
with cyclosporine A for renal transplant [97]. At the mo-
ment, as long-term safety data on the use of rituximab
in pediatric vasculitis are still missing, rituximab should
be prescribed carefully, in refractory cases. A phase IIa
international open-label trial is currently recruiting
patients to evaluate the safety and pharmacokinetics of
rituximab in children with severe GPA or MPA (PePRS
study, NCT01750697), but mechanical ventilation due to
alveolar hemorrhage represents an exclusion criterium
for participation in the study. It should be noted that
also the RAVE trial excluded patients with alveolar hae-
morrage requiring mechanical respiratory assistance
upon enrollment [94].
A retrospective study analyzing a cohort of patients
with alveolar haemorrage secondary to AAV, including
also patients needing mechanical ventilation, showed
that complete remission by 6 months was achieved in a
higher proportion of cases with rituximab than with
cyclophosphamide, even though the use of rituximab
was not associated with a higher long-term survival rate.
The same study could not demonstrate plasma exchange
efficacy in addition to the standard remission induction
therapy [47].
Lung disease can also necessitate the use of support-
ive measures. Pulmonary haemorrhage may require
ventilator support in an intensive care unit setting or
even extracorporeal membrane oxygenation [20, 98].
Akikusa and colleagues reported a median duration of
intubation of 8 days in the subgroup of children requir-
ing ventilation [22].
Airway lesions rarely respond satisfactorily to systemic
therapy with cyclophosphamide, but rituximab appeared
to be a more efficient therapy for tracheobronchial
lesions [35, 99, 100]. In the presence of subglottic or
tracheal involvement, surgical intervention is often
needed to maintain a patent airway [101–103].
Conclusion
Lung involvement is a common manifestation in chil-
dren affected by GPA. Its severity is variable, ranging
from asymptomatic pulmonary lesions to dramatic life-
threatening clinical presentations such as diffuse alveolar
haemorrhage. Several radiologic findings have been
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described, but the most frequent abnormalities detected
are nodular lesions and fixed infiltrates. Nodular lung le-
sions tend to regress with immunosuppressive therapy,
but lung disease may also require second line treat-
ments. Rituximab may represent a promising treatment
option also in pediatric patients, even if its efficacy and
safety in children should be better studied. In cases of
massive diffuse alveolar haemorrhage, ventilator support
is crucial in the management of the patient.
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